GSK melanoma pill backed by UK cost watchdog with price cut

September 17, 2014 11:11 PM

10 0

GSK melanoma pill backed by UK cost watchdog with price cut

LONDON (Reuters) - Britain's healthcare cost agency NICE has recommended a third new drug for melanoma, this time from GlaxoSmithKline, after the drugmaker offered to supply it at a discount to the state-run National Health Service.

GSK currently markets Tafinlar but the product will soon transfer to Novartis under a deal between the two companies to trade assets.

Also watch: Illinois hires Oklahoma State's Brad Underwood, who's in for a nice raise

Read more

To category page

Loading...